LONDON — Scientists have achieved what many in the healthcare industry considered unthinkable: a virus that effectively halts pancreatic cancer. Early trials of the Oncolytic Vax-3, administered to three patients, showed complete cessation of tumor growth and spread, triggering immediate panic among pharmaceutical executives whose entire business model relies on managing, not eliminating, terminal disease.
"This is a serious setback for shareholder value and frankly, for the entire concept of sustainable quarterly growth," stated Dr. Alistair Finch, CEO of PharmaCorp Global, in an emergency internal memo obtained by Hambry. "While we applaud the scientific community's dedication, a full cure for a leading cause of death could devalue our existing oncology portfolio by trillions. We simply cannot sustain innovation in an environment where patients are cured without decades of recurring prescriptions, follow-up treatments, and the constant threat of relapse driving demand for new-and-improved symptom management."
Industry analysts quickly downgraded the entire medical sector, predicting a mass exodus of investors from companies specializing in palliative care, chemotherapy, and end-of-life pharmaceuticals. "It's a logistical nightmare," explained Millicent Hayes, a healthcare pricing strategist at Goldman Sachs, during a tearful press conference held simultaneously with a 'GoFundMe' for her upcoming yacht payments. "How do you justify a $150,000 annual premium for a disease that no longer exists? The entire value proposition collapses. We're looking at a complete restructuring, possibly into the far less profitable wellness or prevention markets, which honestly, sounds like socialism."
Sources close to the FDA indicate that Oncolytic Vax-3 will likely undergo an "accelerated 30-year approval process," citing concerns over "long-term societal impact" and "disrupting established economic ecosystems." An anonymous official added, "We need to ensure proper market stability. Rushing a cure to market sets a dangerous precedent, implying that health should take precedence over shareholder dividends. Think of the precedent for other diseases! What if they cure diabetes next? The entire global economy would collapse." The drug is expected to retail at $7.5 million per dose, available exclusively to patients with platinum-tier insurance plans that specifically cover "miracles that threaten our bottom line."
Meanwhile, the three patients, now inexplicably cancer-free, have been asked to sign non-disclosure agreements regarding their improved health status. The fine print stipulates that any public discussion of their recovery will result in immediate repossession of their kidneys to "offset potential market volatility caused by unrealistic expectations." Their doctors, however, have been generously offered lucrative consulting gigs to "study the long-term emotional impact of unexpected good news."
